#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Differentiating the Effects of Familial Risk for Alcohol Dependence and Prenatal Exposure to Alcohol on Offspring Brain Morphology BACKGROUND Offspring with a family history of alcohol dependence (AD) have been shown to have altered structural and functional integrity of corticolimbic brain structures.
1-1	0-15	Differentiating	_
1-2	16-19	the	_
1-3	20-27	Effects	_
1-4	28-30	of	_
1-5	31-39	Familial	_
1-6	40-44	Risk	_
1-7	45-48	for	_
1-8	49-56	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-9	57-67	Dependence	_
1-10	68-71	and	_
1-11	72-80	Prenatal	_
1-12	81-89	Exposure	_
1-13	90-92	to	_
1-14	93-100	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-15	101-103	on	_
1-16	104-113	Offspring	_
1-17	114-119	Brain	_
1-18	120-130	Morphology	_
1-19	131-141	BACKGROUND	_
1-20	142-151	Offspring	_
1-21	152-156	with	_
1-22	157-158	a	_
1-23	159-165	family	_
1-24	166-173	history	_
1-25	174-176	of	_
1-26	177-184	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-27	185-195	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-28	196-197	(	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-29	198-200	AD	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-30	201-202	)	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-31	203-207	have	_
1-32	208-212	been	_
1-33	213-218	shown	_
1-34	219-221	to	_
1-35	222-226	have	_
1-36	227-234	altered	_
1-37	235-245	structural	_
1-38	246-249	and	_
1-39	250-260	functional	_
1-40	261-270	integrity	_
1-41	271-273	of	_
1-42	274-287	corticolimbic	_
1-43	288-293	brain	_
1-44	294-304	structures	_
1-45	305-306	.	_

Text=Similarly, prenatal exposure to alcohol is associated with a variety of structural and functional brain changes.
2-1	307-316	Similarly	_
2-2	317-318	,	_
2-3	319-327	prenatal	_
2-4	328-336	exposure	_
2-5	337-339	to	_
2-6	340-347	alcohol	_
2-7	348-350	is	_
2-8	351-361	associated	_
2-9	362-366	with	_
2-10	367-368	a	_
2-11	369-376	variety	_
2-12	377-379	of	_
2-13	380-390	structural	_
2-14	391-394	and	_
2-15	395-405	functional	_
2-16	406-411	brain	_
2-17	412-419	changes	_
2-18	420-421	.	_

Text=The goal of this study was to differentiate the brain gray matter volumetric differences associated with familial risk and prenatal exposure to alcohol among offspring while controlling for lifetime personal exposures to alcohol and drugs.
3-1	422-425	The	_
3-2	426-430	goal	_
3-3	431-433	of	_
3-4	434-438	this	_
3-5	439-444	study	_
3-6	445-448	was	_
3-7	449-451	to	_
3-8	452-465	differentiate	_
3-9	466-469	the	_
3-10	470-475	brain	_
3-11	476-480	gray	_
3-12	481-487	matter	_
3-13	488-498	volumetric	_
3-14	499-510	differences	_
3-15	511-521	associated	_
3-16	522-526	with	_
3-17	527-535	familial	_
3-18	536-540	risk	_
3-19	541-544	and	_
3-20	545-553	prenatal	_
3-21	554-562	exposure	_
3-22	563-565	to	_
3-23	566-573	alcohol	_
3-24	574-579	among	_
3-25	580-589	offspring	_
3-26	590-595	while	_
3-27	596-607	controlling	_
3-28	608-611	for	_
3-29	612-620	lifetime	_
3-30	621-629	personal	_
3-31	630-639	exposures	_
3-32	640-642	to	_
3-33	643-650	alcohol	_
3-34	651-654	and	_
3-35	655-660	drugs	_
3-36	661-662	.	_

Text=METHODS A total of 52 high-risk (HR) offspring from maternal multiplex families with a high proportion of alcohol dependence were studied along with 55 low-risk (LR) offspring.
4-1	663-670	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
4-2	671-672	A	_
4-3	673-678	total	_
4-4	679-681	of	_
4-5	682-684	52	_
4-6	685-694	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
4-7	695-696	(	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
4-8	697-699	HR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
4-9	700-701	)	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
4-10	702-711	offspring	_
4-11	712-716	from	_
4-12	717-725	maternal	_
4-13	726-735	multiplex	_
4-14	736-744	families	_
4-15	745-749	with	_
4-16	750-751	a	_
4-17	752-756	high	_
4-18	757-767	proportion	_
4-19	768-770	of	_
4-20	771-778	alcohol	_
4-21	779-789	dependence	_
4-22	790-794	were	_
4-23	795-802	studied	_
4-24	803-808	along	_
4-25	809-813	with	_
4-26	814-816	55	_
4-27	817-825	low-risk	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
4-28	826-827	(	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
4-29	828-830	LR	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
4-30	831-832	)	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
4-31	833-842	offspring	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
4-32	843-844	.	_

Text=Voxel based morphometric (VBM) analysis was performed using statistical parametric mapping (SPM8) software using 3T structural images from these offspring to identify gray matter volume differences associated with familial risk and prenatal exposure.
5-1	845-850	Voxel	_
5-2	851-856	based	_
5-3	857-869	morphometric	_
5-4	870-871	(	_
5-5	872-875	VBM	_
5-6	876-877	)	_
5-7	878-886	analysis	_
5-8	887-890	was	_
5-9	891-900	performed	_
5-10	901-906	using	_
5-11	907-918	statistical	_
5-12	919-929	parametric	_
5-13	930-937	mapping	_
5-14	938-939	(	_
5-15	940-944	SPM8	_
5-16	945-946	)	_
5-17	947-955	software	_
5-18	956-961	using	_
5-19	962-964	3T	_
5-20	965-975	structural	_
5-21	976-982	images	_
5-22	983-987	from	_
5-23	988-993	these	_
5-24	994-1003	offspring	_
5-25	1004-1006	to	_
5-26	1007-1015	identify	_
5-27	1016-1020	gray	_
5-28	1021-1027	matter	_
5-29	1028-1034	volume	_
5-30	1035-1046	differences	_
5-31	1047-1057	associated	_
5-32	1058-1062	with	_
5-33	1063-1071	familial	_
5-34	1072-1076	risk	_
5-35	1077-1080	and	_
5-36	1081-1089	prenatal	_
5-37	1090-1098	exposure	_
5-38	1099-1100	.	_

Text=RESULTS Significant familial risk group differences were seen with HR males showing reduced volume of the left inferior temporal, left fusiform and left and right insula regions relative to LR males, controlling for prenatal exposure to alcohol drugs and cigarettes.
6-1	1101-1108	RESULTS	_
6-2	1109-1120	Significant	_
6-3	1121-1129	familial	_
6-4	1130-1134	risk	_
6-5	1135-1140	group	_
6-6	1141-1152	differences	_
6-7	1153-1157	were	_
6-8	1158-1162	seen	_
6-9	1163-1167	with	_
6-10	1168-1170	HR	_
6-11	1171-1176	males	_
6-12	1177-1184	showing	_
6-13	1185-1192	reduced	_
6-14	1193-1199	volume	_
6-15	1200-1202	of	_
6-16	1203-1206	the	_
6-17	1207-1211	left	_
6-18	1212-1220	inferior	_
6-19	1221-1229	temporal	_
6-20	1230-1231	,	_
6-21	1232-1236	left	_
6-22	1237-1245	fusiform	_
6-23	1246-1249	and	_
6-24	1250-1254	left	_
6-25	1255-1258	and	_
6-26	1259-1264	right	_
6-27	1265-1271	insula	_
6-28	1272-1279	regions	_
6-29	1280-1288	relative	_
6-30	1289-1291	to	_
6-31	1292-1294	LR	_
6-32	1295-1300	males	_
6-33	1301-1302	,	_
6-34	1303-1314	controlling	_
6-35	1315-1318	for	_
6-36	1319-1327	prenatal	_
6-37	1328-1336	exposure	_
6-38	1337-1339	to	_
6-39	1340-1347	alcohol	_
6-40	1348-1353	drugs	_
6-41	1354-1357	and	_
6-42	1358-1368	cigarettes	_
6-43	1369-1370	.	_

Text=High-risk females showed a reduction in the right fusiform but also showed a reduction in volume in portions of the cerebellum (left crus I and left lobe 8).
7-1	1371-1380	High-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
7-2	1381-1388	females	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
7-3	1389-1395	showed	_
7-4	1396-1397	a	_
7-5	1398-1407	reduction	_
7-6	1408-1410	in	_
7-7	1411-1414	the	_
7-8	1415-1420	right	_
7-9	1421-1429	fusiform	_
7-10	1430-1433	but	_
7-11	1434-1438	also	_
7-12	1439-1445	showed	_
7-13	1446-1447	a	_
7-14	1448-1457	reduction	_
7-15	1458-1460	in	_
7-16	1461-1467	volume	_
7-17	1468-1470	in	_
7-18	1471-1479	portions	_
7-19	1480-1482	of	_
7-20	1483-1486	the	_
7-21	1487-1497	cerebellum	_
7-22	1498-1499	(	_
7-23	1500-1504	left	_
7-24	1505-1509	crus	_
7-25	1510-1511	I	_
7-26	1512-1515	and	_
7-27	1516-1520	left	_
7-28	1521-1525	lobe	_
7-29	1526-1527	8	_
7-30	1528-1529	)	_
7-31	1530-1531	.	_

Text=Prenatal alcohol exposure effects, assessed within the familial high-risk group, was associated with reduced right middle cingulum and left middle temporal volume.
8-1	1532-1540	Prenatal	_
8-2	1541-1548	alcohol	_
8-3	1549-1557	exposure	_
8-4	1558-1565	effects	_
8-5	1566-1567	,	_
8-6	1568-1576	assessed	_
8-7	1577-1583	within	_
8-8	1584-1587	the	_
8-9	1588-1596	familial	_
8-10	1597-1606	high-risk	_
8-11	1607-1612	group	_
8-12	1613-1614	,	_
8-13	1615-1618	was	_
8-14	1619-1629	associated	_
8-15	1630-1634	with	_
8-16	1635-1642	reduced	_
8-17	1643-1648	right	_
8-18	1649-1655	middle	_
8-19	1656-1664	cingulum	_
8-20	1665-1668	and	_
8-21	1669-1673	left	_
8-22	1674-1680	middle	_
8-23	1681-1689	temporal	_
8-24	1690-1696	volume	_
8-25	1697-1698	.	_

Text=Even low exposure resulting from mothers drinking in amounts less than the median of those who drank (53 drinks or less over the course of the pregnancy) showed a reduction of volume in the right anterior cingulum and in the left cerebellum (lobes 4 and 5).
9-1	1699-1703	Even	_
9-2	1704-1707	low	_
9-3	1708-1716	exposure	_
9-4	1717-1726	resulting	_
9-5	1727-1731	from	_
9-6	1732-1739	mothers	_
9-7	1740-1748	drinking	_
9-8	1749-1751	in	_
9-9	1752-1759	amounts	_
9-10	1760-1764	less	_
9-11	1765-1769	than	_
9-12	1770-1773	the	_
9-13	1774-1780	median	_
9-14	1781-1783	of	_
9-15	1784-1789	those	_
9-16	1790-1793	who	_
9-17	1794-1799	drank	_
9-18	1800-1801	(	_
9-19	1802-1804	53	_
9-20	1805-1811	drinks	_
9-21	1812-1814	or	_
9-22	1815-1819	less	_
9-23	1820-1824	over	_
9-24	1825-1828	the	_
9-25	1829-1835	course	_
9-26	1836-1838	of	_
9-27	1839-1842	the	_
9-28	1843-1852	pregnancy	_
9-29	1853-1854	)	_
9-30	1855-1861	showed	_
9-31	1862-1863	a	_
9-32	1864-1873	reduction	_
9-33	1874-1876	of	_
9-34	1877-1883	volume	_
9-35	1884-1886	in	_
9-36	1887-1890	the	_
9-37	1891-1896	right	_
9-38	1897-1905	anterior	_
9-39	1906-1914	cingulum	_
9-40	1915-1918	and	_
9-41	1919-1921	in	_
9-42	1922-1925	the	_
9-43	1926-1930	left	_
9-44	1931-1941	cerebellum	_
9-45	1942-1943	(	_
9-46	1944-1949	lobes	_
9-47	1950-1951	4	_
9-48	1952-1955	and	_
9-49	1956-1957	5	_
9-50	1958-1959	)	_
9-51	1960-1961	.	_

Text=CONCLUSIONS Familial risk for alcohol dependence and prenatal exposure to alcohol and other drugs show independent effects on brain morphology.
10-1	1962-1973	CONCLUSIONS	http://maven.renci.org/NeuroBridge/neurobridge#StudyInclusionCriterion
10-2	1974-1982	Familial	_
10-3	1983-1987	risk	_
10-4	1988-1991	for	_
10-5	1992-1999	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
10-6	2000-2010	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
10-7	2011-2014	and	_
10-8	2015-2023	prenatal	_
10-9	2024-2032	exposure	_
10-10	2033-2035	to	_
10-11	2036-2043	alcohol	_
10-12	2044-2047	and	_
10-13	2048-2053	other	_
10-14	2054-2059	drugs	_
10-15	2060-2064	show	_
10-16	2065-2076	independent	_
10-17	2077-2084	effects	_
10-18	2085-2087	on	_
10-19	2088-2093	brain	_
10-20	2094-2104	morphology	_
10-21	2105-2106	.	_

Text=Methods Participants The present report is based on structural MRI (sMRI) scans of 107 third generation offspring who are part of an ongoing family study that selected families through their parents ’ generation.
11-1	2107-2114	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	2115-2127	Participants	_
11-3	2128-2131	The	_
11-4	2132-2139	present	_
11-5	2140-2146	report	_
11-6	2147-2149	is	_
11-7	2150-2155	based	_
11-8	2156-2158	on	_
11-9	2159-2169	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
11-10	2170-2173	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
11-11	2174-2175	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
11-12	2176-2180	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
11-13	2181-2182	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
11-14	2183-2188	scans	_
11-15	2189-2191	of	_
11-16	2192-2195	107	_
11-17	2196-2201	third	_
11-18	2202-2212	generation	_
11-19	2213-2222	offspring	_
11-20	2223-2226	who	_
11-21	2227-2230	are	_
11-22	2231-2235	part	_
11-23	2236-2238	of	_
11-24	2239-2241	an	_
11-25	2242-2249	ongoing	_
11-26	2250-2256	family	_
11-27	2257-2262	study	_
11-28	2263-2267	that	_
11-29	2268-2276	selected	_
11-30	2277-2285	families	_
11-31	2286-2293	through	_
11-32	2294-2299	their	_
11-33	2300-2307	parents	_
11-34	2308-2309	’	_
11-35	2310-2320	generation	_
11-36	2321-2322	.	_

Text=A total of 52 high-risk (HR) offspring from maternal multiplex families with a high proportion of AD were studied along with 55 low-risk (LR) offspring.
12-1	2323-2324	A	_
12-2	2325-2330	total	_
12-3	2331-2333	of	_
12-4	2334-2336	52	_
12-5	2337-2346	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
12-6	2347-2348	(	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
12-7	2349-2351	HR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
12-8	2352-2353	)	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
12-9	2354-2363	offspring	_
12-10	2364-2368	from	_
12-11	2369-2377	maternal	_
12-12	2378-2387	multiplex	_
12-13	2388-2396	families	_
12-14	2397-2401	with	_
12-15	2402-2403	a	_
12-16	2404-2408	high	_
12-17	2409-2419	proportion	_
12-18	2420-2422	of	_
12-19	2423-2425	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-20	2426-2430	were	_
12-21	2431-2438	studied	_
12-22	2439-2444	along	_
12-23	2445-2449	with	_
12-24	2450-2452	55	_
12-25	2453-2461	low-risk	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-26	2462-2463	(	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-27	2464-2466	LR	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-28	2467-2468	)	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-29	2469-2478	offspring	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-30	2479-2480	.	_

Text=All participants in the MRI assessments were part of a larger longitudinal follow-up in which children, adolescents and young adults from high and low-familial risk for AD families were assessed clinically using age appropriate structured instruments.
13-1	2481-2484	All	_
13-2	2485-2497	participants	_
13-3	2498-2500	in	_
13-4	2501-2504	the	_
13-5	2505-2508	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-6	2509-2520	assessments	_
13-7	2521-2525	were	_
13-8	2526-2530	part	_
13-9	2531-2533	of	_
13-10	2534-2535	a	_
13-11	2536-2542	larger	_
13-12	2543-2555	longitudinal	_
13-13	2556-2565	follow-up	_
13-14	2566-2568	in	_
13-15	2569-2574	which	_
13-16	2575-2583	children	_
13-17	2584-2585	,	_
13-18	2586-2597	adolescents	_
13-19	2598-2601	and	_
13-20	2602-2607	young	_
13-21	2608-2614	adults	_
13-22	2615-2619	from	_
13-23	2620-2624	high	_
13-24	2625-2628	and	_
13-25	2629-2641	low-familial	_
13-26	2642-2646	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
13-27	2647-2650	for	_
13-28	2651-2653	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
13-29	2654-2662	families	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
13-30	2663-2667	were	_
13-31	2668-2676	assessed	_
13-32	2677-2687	clinically	_
13-33	2688-2693	using	_
13-34	2694-2697	age	_
13-35	2698-2709	appropriate	_
13-36	2710-2720	structured	_
13-37	2721-2732	instruments	_
13-38	2733-2734	.	_

Text=The offspring were followed through childhood at approximately annual intervals and through young adulthood, biennially.
14-1	2735-2738	The	_
14-2	2739-2748	offspring	_
14-3	2749-2753	were	_
14-4	2754-2762	followed	_
14-5	2763-2770	through	_
14-6	2771-2780	childhood	_
14-7	2781-2783	at	_
14-8	2784-2797	approximately	_
14-9	2798-2804	annual	_
14-10	2805-2814	intervals	_
14-11	2815-2818	and	_
14-12	2819-2826	through	_
14-13	2827-2832	young	_
14-14	2833-2842	adulthood	_
14-15	2843-2844	,	_
14-16	2845-2855	biennially	_
14-17	2856-2857	.	_

Text=These follow-up visits provided extensive assessment of alcohol and drug use information obtained at each follow-up wave.
15-1	2858-2863	These	_
15-2	2864-2873	follow-up	_
15-3	2874-2880	visits	_
15-4	2881-2889	provided	_
15-5	2890-2899	extensive	_
15-6	2900-2910	assessment	_
15-7	2911-2913	of	_
15-8	2914-2921	alcohol	_
15-9	2922-2925	and	_
15-10	2926-2930	drug	_
15-11	2931-2934	use	_
15-12	2935-2946	information	_
15-13	2947-2955	obtained	_
15-14	2956-2958	at	_
15-15	2959-2963	each	_
15-16	2964-2973	follow-up	_
15-17	2974-2978	wave	_
15-18	2979-2980	.	_

Text=All participants provided consent with each visit.
16-1	2981-2984	All	_
16-2	2985-2997	participants	_
16-3	2998-3006	provided	_
16-4	3007-3014	consent	_
16-5	3015-3019	with	_
16-6	3020-3024	each	_
16-7	3025-3030	visit	_
16-8	3031-3032	.	_

Text=Children provided assent with parental consent.
17-1	3033-3041	Children	_
17-2	3042-3050	provided	_
17-3	3051-3057	assent	_
17-4	3058-3062	with	_
17-5	3063-3071	parental	_
17-6	3072-3079	consent	_
17-7	3080-3081	.	_

Text=The study has ongoing approval from the University of Pittsburgh Institutional Review Board.
18-1	3082-3085	The	_
18-2	3086-3091	study	_
18-3	3092-3095	has	_
18-4	3096-3103	ongoing	_
18-5	3104-3112	approval	_
18-6	3113-3117	from	_
18-7	3118-3121	the	_
18-8	3122-3132	University	_
18-9	3133-3135	of	_
18-10	3136-3146	Pittsburgh	_
18-11	3147-3160	Institutional	_
18-12	3161-3167	Review	_
18-13	3168-3173	Board	_
18-14	3174-3175	.	_

Text=High-Risk Families High-risk (HR) families were identified through a proband pair of alcohol dependent sisters.
19-1	3176-3185	High-Risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-2	3186-3194	Families	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-3	3195-3204	High-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-4	3205-3206	(	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-5	3207-3209	HR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-6	3210-3211	)	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-7	3212-3220	families	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-8	3221-3225	were	_
19-9	3226-3236	identified	_
19-10	3237-3244	through	_
19-11	3245-3246	a	_
19-12	3247-3254	proband	_
19-13	3255-3259	pair	_
19-14	3260-3262	of	_
19-15	3263-3270	alcohol	_
19-16	3271-3280	dependent	_
19-17	3281-3288	sisters	_
19-18	3289-3290	.	_

Text=One member of the proband pair was in a substance abuse treatment facility in the Pittsburgh area at the time of recruitment.
20-1	3291-3294	One	_
20-2	3295-3301	member	_
20-3	3302-3304	of	_
20-4	3305-3308	the	_
20-5	3309-3316	proband	_
20-6	3317-3321	pair	_
20-7	3322-3325	was	_
20-8	3326-3328	in	_
20-9	3329-3330	a	_
20-10	3331-3340	substance	_
20-11	3341-3346	abuse	_
20-12	3347-3356	treatment	_
20-13	3357-3365	facility	_
20-14	3366-3368	in	_
20-15	3369-3372	the	_
20-16	3373-3383	Pittsburgh	_
20-17	3384-3388	area	_
20-18	3389-3391	at	_
20-19	3392-3395	the	_
20-20	3396-3400	time	_
20-21	3401-3403	of	_
20-22	3404-3415	recruitment	_
20-23	3416-3417	.	_

Text=The study design provided an ultra-high density of alcoholism in the pedigrees from which these offspring were selected.
21-1	3418-3421	The	_
21-2	3422-3427	study	_
21-3	3428-3434	design	_
21-4	3435-3443	provided	_
21-5	3444-3446	an	_
21-6	3447-3457	ultra-high	_
21-7	3458-3465	density	_
21-8	3466-3468	of	_
21-9	3469-3479	alcoholism	_
21-10	3480-3482	in	_
21-11	3483-3486	the	_
21-12	3487-3496	pedigrees	_
21-13	3497-3501	from	_
21-14	3502-3507	which	_
21-15	3508-3513	these	_
21-16	3514-3523	offspring	_
21-17	3524-3528	were	_
21-18	3529-3537	selected	_
21-19	3538-3539	.	_

Text=In person structured interviews (Diagnostic Interview Schedule [DIS]) of the proband sisters, their spouses, and all available first degree relatives were conducted to determine the presence of axis I psychopathology and AD.
22-1	3540-3542	In	_
22-2	3543-3549	person	_
22-3	3550-3560	structured	_
22-4	3561-3571	interviews	_
22-5	3572-3573	(	_
22-6	3574-3584	Diagnostic	_
22-7	3585-3594	Interview	_
22-8	3595-3603	Schedule	_
22-9	3604-3605	[	_
22-10	3606-3609	DIS	_
22-11	3610-3611	]	_
22-12	3612-3613	)	_
22-13	3614-3616	of	_
22-14	3617-3620	the	_
22-15	3621-3628	proband	_
22-16	3629-3636	sisters	_
22-17	3637-3638	,	_
22-18	3639-3644	their	_
22-19	3645-3652	spouses	_
22-20	3653-3654	,	_
22-21	3655-3658	and	_
22-22	3659-3662	all	_
22-23	3663-3672	available	_
22-24	3673-3678	first	_
22-25	3679-3685	degree	_
22-26	3686-3695	relatives	_
22-27	3696-3700	were	_
22-28	3701-3710	conducted	_
22-29	3711-3713	to	_
22-30	3714-3723	determine	_
22-31	3724-3727	the	_
22-32	3728-3736	presence	_
22-33	3737-3739	of	_
22-34	3740-3744	axis	_
22-35	3745-3746	I	_
22-36	3747-3762	psychopathology	_
22-37	3763-3766	and	_
22-38	3767-3769	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
22-39	3770-3771	.	_

Text=Families were excluded if there was presence of bipolar disorder, schizophrenia, recurrent major depression, and drug dependence (i.e.
23-1	3772-3780	Families	_
23-2	3781-3785	were	_
23-3	3786-3794	excluded	_
23-4	3795-3797	if	_
23-5	3798-3803	there	_
23-6	3804-3807	was	_
23-7	3808-3816	presence	_
23-8	3817-3819	of	_
23-9	3820-3827	bipolar	_
23-10	3828-3836	disorder	_
23-11	3837-3838	,	_
23-12	3839-3852	schizophrenia	_
23-13	3853-3854	,	_
23-14	3855-3864	recurrent	_
23-15	3865-3870	major	_
23-16	3871-3881	depression	_
23-17	3882-3883	,	_
23-18	3884-3887	and	_
23-19	3888-3892	drug	_
23-20	3893-3903	dependence	_
23-21	3904-3905	(	_
23-22	3906-3909	i.e	_
23-23	3910-3911	.	_

Text=drug dependence preceded AD by 1 or more years) among proband sisters and their first degree relatives.
24-1	3912-3916	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
24-2	3917-3927	dependence	_
24-3	3928-3936	preceded	_
24-4	3937-3939	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
24-5	3940-3942	by	_
24-6	3943-3944	1	_
24-7	3945-3947	or	_
24-8	3948-3952	more	_
24-9	3953-3958	years	_
24-10	3959-3960	)	_
24-11	3961-3966	among	_
24-12	3967-3974	proband	_
24-13	3975-3982	sisters	_
24-14	3983-3986	and	_
24-15	3987-3992	their	_
24-16	3993-3998	first	_
24-17	3999-4005	degree	_
24-18	4006-4015	relatives	_
24-19	4016-4017	.	_

Text=Low-Risk Control Families Each control family was initially recruited by place of residence and whether children between the ages of 8–18 lived within the home.
25-1	4018-4026	Low-Risk	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
25-2	4027-4034	Control	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
25-3	4035-4043	Families	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
25-4	4044-4048	Each	_
25-5	4049-4056	control	_
25-6	4057-4063	family	_
25-7	4064-4067	was	_
25-8	4068-4077	initially	_
25-9	4078-4087	recruited	_
25-10	4088-4090	by	_
25-11	4091-4096	place	_
25-12	4097-4099	of	_
25-13	4100-4109	residence	_
25-14	4110-4113	and	_
25-15	4114-4121	whether	_
25-16	4122-4130	children	_
25-17	4131-4138	between	_
25-18	4139-4142	the	_
25-19	4143-4147	ages	_
25-20	4148-4150	of	_
25-21	4151-4155	8–18	_
25-22	4156-4161	lived	_
25-23	4162-4168	within	_
25-24	4169-4172	the	_
25-25	4173-4177	home	_
25-26	4178-4179	.	_

Text=Each control family was selected for their residence within a census track from which a high-risk family had been selected.
26-1	4180-4184	Each	_
26-2	4185-4192	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
26-3	4193-4199	family	_
26-4	4200-4203	was	_
26-5	4204-4212	selected	_
26-6	4213-4216	for	_
26-7	4217-4222	their	_
26-8	4223-4232	residence	_
26-9	4233-4239	within	_
26-10	4240-4241	a	_
26-11	4242-4248	census	_
26-12	4249-4254	track	_
26-13	4255-4259	from	_
26-14	4260-4265	which	_
26-15	4266-4267	a	_
26-16	4268-4277	high-risk	_
26-17	4278-4284	family	_
26-18	4285-4288	had	_
26-19	4289-4293	been	_
26-20	4294-4302	selected	_
26-21	4303-4304	.	_

Text=This provided a yoked control for neighborhood characteristics.
27-1	4305-4309	This	_
27-2	4310-4318	provided	_
27-3	4319-4320	a	_
27-4	4321-4326	yoked	_
27-5	4327-4334	control	_
27-6	4335-4338	for	_
27-7	4339-4351	neighborhood	_
27-8	4352-4367	characteristics	_
27-9	4368-4369	.	_

Text=Families qualifying by these characteristics were further screened to determine the psychopathology within the family.
28-1	4370-4378	Families	_
28-2	4379-4389	qualifying	_
28-3	4390-4392	by	_
28-4	4393-4398	these	_
28-5	4399-4414	characteristics	_
28-6	4415-4419	were	_
28-7	4420-4427	further	_
28-8	4428-4436	screened	_
28-9	4437-4439	to	_
28-10	4440-4449	determine	_
28-11	4450-4453	the	_
28-12	4454-4469	psychopathology	_
28-13	4470-4476	within	_
28-14	4477-4480	the	_
28-15	4481-4487	family	_
28-16	4488-4489	.	_

Text=Mothers were designated as the "index" case and screened for absence of alcohol and drug dependence using the DIS, though other psychopathology was free to vary with the exception of schizophrenia and bipolar disorder.
29-1	4490-4497	Mothers	_
29-2	4498-4502	were	_
29-3	4503-4513	designated	_
29-4	4514-4516	as	_
29-5	4517-4520	the	_
29-6	4521-4523	``	_
29-7	4524-4529	index	_
29-8	4530-4532	''	_
29-9	4533-4537	case	_
29-10	4538-4541	and	_
29-11	4542-4550	screened	_
29-12	4551-4554	for	_
29-13	4555-4562	absence	_
29-14	4563-4565	of	_
29-15	4566-4573	alcohol	_
29-16	4574-4577	and	_
29-17	4578-4582	drug	_
29-18	4583-4593	dependence	_
29-19	4594-4599	using	_
29-20	4600-4603	the	_
29-21	4604-4607	DIS	_
29-22	4608-4609	,	_
29-23	4610-4616	though	_
29-24	4617-4622	other	_
29-25	4623-4638	psychopathology	_
29-26	4639-4642	was	_
29-27	4643-4647	free	_
29-28	4648-4650	to	_
29-29	4651-4655	vary	_
29-30	4656-4660	with	_
29-31	4661-4664	the	_
29-32	4665-4674	exception	_
29-33	4675-4677	of	_
29-34	4678-4691	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
29-35	4692-4695	and	_
29-36	4696-4703	bipolar	_
29-37	4704-4712	disorder	_
29-38	4713-4714	.	_

Text=Diagnostic data were also collected for all first degree relatives using either an in-person DIS interview or by obtaining multiple family history reports to ensure an absence of a family history of AD.
30-1	4715-4725	Diagnostic	_
30-2	4726-4730	data	_
30-3	4731-4735	were	_
30-4	4736-4740	also	_
30-5	4741-4750	collected	_
30-6	4751-4754	for	_
30-7	4755-4758	all	_
30-8	4759-4764	first	_
30-9	4765-4771	degree	_
30-10	4772-4781	relatives	_
30-11	4782-4787	using	_
30-12	4788-4794	either	_
30-13	4795-4797	an	_
30-14	4798-4807	in-person	_
30-15	4808-4811	DIS	_
30-16	4812-4821	interview	_
30-17	4822-4824	or	_
30-18	4825-4827	by	_
30-19	4828-4837	obtaining	_
30-20	4838-4846	multiple	_
30-21	4847-4853	family	_
30-22	4854-4861	history	_
30-23	4862-4869	reports	_
30-24	4870-4872	to	_
30-25	4873-4879	ensure	_
30-26	4880-4882	an	_
30-27	4883-4890	absence	_
30-28	4891-4893	of	_
30-29	4894-4895	a	_
30-30	4896-4902	family	_
30-31	4903-4910	history	_
30-32	4911-4913	of	_
30-33	4914-4916	AD	_
30-34	4917-4918	.	_

Text=Accordingly, all control families had a low density of familial AD.
31-1	4919-4930	Accordingly	_
31-2	4931-4932	,	_
31-3	4933-4936	all	_
31-4	4937-4944	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-5	4945-4953	families	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-6	4954-4957	had	_
31-7	4958-4959	a	_
31-8	4960-4963	low	_
31-9	4964-4971	density	_
31-10	4972-4974	of	_
31-11	4975-4983	familial	_
31-12	4984-4986	AD	_
31-13	4987-4988	.	_

Text=Assessment of Personal Exposure All participants were part of a longitudinal study that allowed determination of quantitative estimates of cigarette and alcohol use.
32-1	4989-4999	Assessment	_
32-2	5000-5002	of	_
32-3	5003-5011	Personal	_
32-4	5012-5020	Exposure	_
32-5	5021-5024	All	_
32-6	5025-5037	participants	_
32-7	5038-5042	were	_
32-8	5043-5047	part	_
32-9	5048-5050	of	_
32-10	5051-5052	a	_
32-11	5053-5065	longitudinal	_
32-12	5066-5071	study	_
32-13	5072-5076	that	_
32-14	5077-5084	allowed	_
32-15	5085-5098	determination	_
32-16	5099-5101	of	_
32-17	5102-5114	quantitative	_
32-18	5115-5124	estimates	_
32-19	5125-5127	of	_
32-20	5128-5137	cigarette	_
32-21	5138-5141	and	_
32-22	5142-5149	alcohol	_
32-23	5150-5153	use	_
32-24	5154-5155	.	_

Text=Exposure to cigarettes and alcohol up to the time of the scan was calculated based on the longitudinally acquired data.
33-1	5156-5164	Exposure	_
33-2	5165-5167	to	_
33-3	5168-5178	cigarettes	_
33-4	5179-5182	and	_
33-5	5183-5190	alcohol	_
33-6	5191-5193	up	_
33-7	5194-5196	to	_
33-8	5197-5200	the	_
33-9	5201-5205	time	_
33-10	5206-5208	of	_
33-11	5209-5212	the	_
33-12	5213-5217	scan	_
33-13	5218-5221	was	_
33-14	5222-5232	calculated	_
33-15	5233-5238	based	_
33-16	5239-5241	on	_
33-17	5242-5245	the	_
33-18	5246-5260	longitudinally	_
33-19	5261-5269	acquired	_
33-20	5270-5274	data	_
33-21	5275-5276	.	_

Text=Because alcohol and cigarettes were the most commonly used substances, values for lifetime use of alcohol and cigarettes and whether the individual met criteria for a substance use disorder before the scan were used as covariates in both VBM and SPSS analyses.
34-1	5277-5284	Because	_
34-2	5285-5292	alcohol	_
34-3	5293-5296	and	_
34-4	5297-5307	cigarettes	_
34-5	5308-5312	were	_
34-6	5313-5316	the	_
34-7	5317-5321	most	_
34-8	5322-5330	commonly	_
34-9	5331-5335	used	_
34-10	5336-5346	substances	_
34-11	5347-5348	,	_
34-12	5349-5355	values	_
34-13	5356-5359	for	_
34-14	5360-5368	lifetime	_
34-15	5369-5372	use	_
34-16	5373-5375	of	_
34-17	5376-5383	alcohol	_
34-18	5384-5387	and	_
34-19	5388-5398	cigarettes	_
34-20	5399-5402	and	_
34-21	5403-5410	whether	_
34-22	5411-5414	the	_
34-23	5415-5425	individual	_
34-24	5426-5429	met	_
34-25	5430-5438	criteria	_
34-26	5439-5442	for	_
34-27	5443-5444	a	_
34-28	5445-5454	substance	_
34-29	5455-5458	use	_
34-30	5459-5467	disorder	_
34-31	5468-5474	before	_
34-32	5475-5478	the	_
34-33	5479-5483	scan	_
34-34	5484-5488	were	_
34-35	5489-5493	used	_
34-36	5494-5496	as	_
34-37	5497-5507	covariates	_
34-38	5508-5510	in	_
34-39	5511-5515	both	_
34-40	5516-5519	VBM	_
34-41	5520-5523	and	_
34-42	5524-5528	SPSS	_
34-43	5529-5537	analyses	_
34-44	5538-5539	.	_

Text=Assessment of Prenatal Use of Substances Mothers of the offspring included in the present report were administered a structured interview concerning their drinking, smoking, and drug usage during pregnancy.
35-1	5540-5550	Assessment	_
35-2	5551-5553	of	_
35-3	5554-5562	Prenatal	_
35-4	5563-5566	Use	_
35-5	5567-5569	of	_
35-6	5570-5580	Substances	_
35-7	5581-5588	Mothers	_
35-8	5589-5591	of	_
35-9	5592-5595	the	_
35-10	5596-5605	offspring	_
35-11	5606-5614	included	_
35-12	5615-5617	in	_
35-13	5618-5621	the	_
35-14	5622-5629	present	_
35-15	5630-5636	report	_
35-16	5637-5641	were	_
35-17	5642-5654	administered	_
35-18	5655-5656	a	_
35-19	5657-5667	structured	_
35-20	5668-5677	interview	_
35-21	5678-5688	concerning	_
35-22	5689-5694	their	_
35-23	5695-5703	drinking	_
35-24	5704-5705	,	_
35-25	5706-5713	smoking	_
35-26	5714-5715	,	_
35-27	5716-5719	and	_
35-28	5720-5724	drug	_
35-29	5725-5730	usage	_
35-30	5731-5737	during	_
35-31	5738-5747	pregnancy	_
35-32	5748-5749	.	_

Text=The interview was performed on the occasion of the first follow-up visit to the laboratory when children were on average 12.1 ± 3.3 years of age.
36-1	5750-5753	The	_
36-2	5754-5763	interview	_
36-3	5764-5767	was	_
36-4	5768-5777	performed	_
36-5	5778-5780	on	_
36-6	5781-5784	the	_
36-7	5785-5793	occasion	_
36-8	5794-5796	of	_
36-9	5797-5800	the	_
36-10	5801-5806	first	_
36-11	5807-5816	follow-up	_
36-12	5817-5822	visit	_
36-13	5823-5825	to	_
36-14	5826-5829	the	_
36-15	5830-5840	laboratory	_
36-16	5841-5845	when	_
36-17	5846-5854	children	_
36-18	5855-5859	were	_
36-19	5860-5862	on	_
36-20	5863-5870	average	_
36-21	5871-5875	12.1	_
36-22	5876-5877	±	_
36-23	5878-5881	3.3	_
36-24	5882-5887	years	_
36-25	5888-5890	of	_
36-26	5891-5894	age	_
36-27	5895-5896	.	_

Text=The interview was designed in our laboratory with the goal of measuring quantity and frequency of drugs, alcohol, and cigarettes during each trimester of pregnancy.
37-1	5897-5900	The	_
37-2	5901-5910	interview	_
37-3	5911-5914	was	_
37-4	5915-5923	designed	_
37-5	5924-5926	in	_
37-6	5927-5930	our	_
37-7	5931-5941	laboratory	_
37-8	5942-5946	with	_
37-9	5947-5950	the	_
37-10	5951-5955	goal	_
37-11	5956-5958	of	_
37-12	5959-5968	measuring	_
37-13	5969-5977	quantity	_
37-14	5978-5981	and	_
37-15	5982-5991	frequency	_
37-16	5992-5994	of	_
37-17	5995-6000	drugs	_
37-18	6001-6002	,	_
37-19	6003-6010	alcohol	_
37-20	6011-6012	,	_
37-21	6013-6016	and	_
37-22	6017-6027	cigarettes	_
37-23	6028-6034	during	_
37-24	6035-6039	each	_
37-25	6040-6049	trimester	_
37-26	6050-6052	of	_
37-27	6053-6062	pregnancy	_
37-28	6063-6064	.	_

Text=Mothers with multiple children were queried concerning each child separately.
38-1	6065-6072	Mothers	_
38-2	6073-6077	with	_
38-3	6078-6086	multiple	_
38-4	6087-6095	children	_
38-5	6096-6100	were	_
38-6	6101-6108	queried	_
38-7	6109-6119	concerning	_
38-8	6120-6124	each	_
38-9	6125-6130	child	_
38-10	6131-6141	separately	_
38-11	6142-6143	.	_

Text=Three prenatal measures were derived from the interview of the mother: prenatal alcohol exposure (quantified as number of drinks during pregnancy), prenatal cigarettes exposure (number of cigarettes smoked during pregnancy), and number of drug days (representing number of days during pregnancy that the mother reported using drugs).
39-1	6144-6149	Three	_
39-2	6150-6158	prenatal	_
39-3	6159-6167	measures	_
39-4	6168-6172	were	_
39-5	6173-6180	derived	_
39-6	6181-6185	from	_
39-7	6186-6189	the	_
39-8	6190-6199	interview	_
39-9	6200-6202	of	_
39-10	6203-6206	the	_
39-11	6207-6213	mother	_
39-12	6214-6215	:	_
39-13	6216-6224	prenatal	_
39-14	6225-6232	alcohol	_
39-15	6233-6241	exposure	_
39-16	6242-6243	(	_
39-17	6244-6254	quantified	_
39-18	6255-6257	as	_
39-19	6258-6264	number	_
39-20	6265-6267	of	_
39-21	6268-6274	drinks	_
39-22	6275-6281	during	_
39-23	6282-6291	pregnancy	_
39-24	6292-6293	)	_
39-25	6294-6295	,	_
39-26	6296-6304	prenatal	_
39-27	6305-6315	cigarettes	_
39-28	6316-6324	exposure	_
39-29	6325-6326	(	_
39-30	6327-6333	number	_
39-31	6334-6336	of	_
39-32	6337-6347	cigarettes	_
39-33	6348-6354	smoked	_
39-34	6355-6361	during	_
39-35	6362-6371	pregnancy	_
39-36	6372-6373	)	_
39-37	6374-6375	,	_
39-38	6376-6379	and	_
39-39	6380-6386	number	_
39-40	6387-6389	of	_
39-41	6390-6394	drug	_
39-42	6395-6399	days	_
39-43	6400-6401	(	_
39-44	6402-6414	representing	_
39-45	6415-6421	number	_
39-46	6422-6424	of	_
39-47	6425-6429	days	_
39-48	6430-6436	during	_
39-49	6437-6446	pregnancy	_
39-50	6447-6451	that	_
39-51	6452-6455	the	_
39-52	6456-6462	mother	_
39-53	6463-6471	reported	_
39-54	6472-6477	using	_
39-55	6478-6483	drugs	_
39-56	6484-6485	)	_
39-57	6486-6487	.	_

Text=Imaging Parameters The MRI scans were performed at the University of Pittsburgh Medical Center (UPMC) Magnetic Resonance Research Center (MRRC) using a 3T Siemens Trio scanner (Siemens Medical Systems, Ehrlangen, Germany) equipped with a fast gradient system for echoplanar imaging.
40-1	6488-6495	Imaging	_
40-2	6496-6506	Parameters	_
40-3	6507-6510	The	_
40-4	6511-6514	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-5	6515-6520	scans	_
40-6	6521-6525	were	_
40-7	6526-6535	performed	_
40-8	6536-6538	at	_
40-9	6539-6542	the	_
40-10	6543-6553	University	_
40-11	6554-6556	of	_
40-12	6557-6567	Pittsburgh	_
40-13	6568-6575	Medical	_
40-14	6576-6582	Center	_
40-15	6583-6584	(	_
40-16	6585-6589	UPMC	_
40-17	6590-6591	)	_
40-18	6592-6600	Magnetic	_
40-19	6601-6610	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#ResearchStudy
40-20	6611-6619	Research	http://maven.renci.org/NeuroBridge/neurobridge#ResearchStudy
40-21	6620-6626	Center	_
40-22	6627-6628	(	_
40-23	6629-6633	MRRC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
40-24	6634-6635	)	_
40-25	6636-6641	using	_
40-26	6642-6643	a	_
40-27	6644-6646	3T	_
40-28	6647-6654	Siemens	_
40-29	6655-6659	Trio	_
40-30	6660-6667	scanner	_
40-31	6668-6669	(	_
40-32	6670-6677	Siemens	_
40-33	6678-6685	Medical	_
40-34	6686-6693	Systems	_
40-35	6694-6695	,	_
40-36	6696-6705	Ehrlangen	_
40-37	6706-6707	,	_
40-38	6708-6715	Germany	_
40-39	6716-6717	)	_
40-40	6718-6726	equipped	_
40-41	6727-6731	with	_
40-42	6732-6733	a	_
40-43	6734-6738	fast	_
40-44	6739-6747	gradient	_
40-45	6748-6754	system	_
40-46	6755-6758	for	_
40-47	6759-6769	echoplanar	_
40-48	6770-6777	imaging	_
40-49	6778-6779	.	_

Text=A standard radio frequency head coil was used with foam padding to restrict head motion.
41-1	6780-6781	A	_
41-2	6782-6790	standard	_
41-3	6791-6796	radio	_
41-4	6797-6806	frequency	_
41-5	6807-6811	head	_
41-6	6812-6816	coil	_
41-7	6817-6820	was	_
41-8	6821-6825	used	_
41-9	6826-6830	with	_
41-10	6831-6835	foam	_
41-11	6836-6843	padding	_
41-12	6844-6846	to	_
41-13	6847-6855	restrict	_
41-14	6856-6860	head	_
41-15	6861-6867	motion	_
41-16	6868-6869	.	_

Text=A 7-min 3D T1-weighted Magnetization Prepared Rapid Gradient Echo Imaging (MPRAGE) sequence (TR=2300ms, TE=2.98 ms, FA=9°, field of view FOV=240mm, acquisition matrix = 240 × 256, in-plane resolution 1.0×1.0 mm2, yielding 160 transversal slices with a thickness of 1.2mm) was used to acquire a high-resolution anatomical scan for VBM analysis.
42-1	6870-6871	A	_
42-2	6872-6877	7-min	_
42-3	6878-6880	3D	_
42-4	6881-6892	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-5	6893-6906	Magnetization	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-6	6907-6915	Prepared	_
42-7	6916-6921	Rapid	_
42-8	6922-6930	Gradient	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-9	6931-6935	Echo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-10	6936-6943	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-11	6944-6945	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-12	6946-6952	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-13	6953-6954	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-14	6955-6963	sequence	_
42-15	6964-6965	(	_
42-16	6966-6975	TR=2300ms	_
42-17	6976-6977	,	_
42-18	6978-6985	TE=2.98	_
42-19	6986-6988	ms	_
42-20	6989-6990	,	_
42-21	6991-6996	FA=9°	_
42-22	6997-6998	,	_
42-23	6999-7004	field	_
42-24	7005-7007	of	_
42-25	7008-7012	view	_
42-26	7013-7022	FOV=240mm	_
42-27	7023-7024	,	_
42-28	7025-7036	acquisition	_
42-29	7037-7043	matrix	_
42-30	7044-7045	=	_
42-31	7046-7049	240	_
42-32	7050-7051	×	_
42-33	7052-7055	256	_
42-34	7056-7057	,	_
42-35	7058-7066	in-plane	_
42-36	7067-7077	resolution	_
42-37	7078-7085	1.0×1.0	_
42-38	7086-7089	mm2	_
42-39	7090-7091	,	_
42-40	7092-7100	yielding	_
42-41	7101-7104	160	_
42-42	7105-7116	transversal	_
42-43	7117-7123	slices	_
42-44	7124-7128	with	_
42-45	7129-7130	a	_
42-46	7131-7140	thickness	_
42-47	7141-7143	of	_
42-48	7144-7149	1.2mm	_
42-49	7150-7151	)	_
42-50	7152-7155	was	_
42-51	7156-7160	used	_
42-52	7161-7163	to	_
42-53	7164-7171	acquire	_
42-54	7172-7173	a	_
42-55	7174-7189	high-resolution	_
42-56	7190-7200	anatomical	_
42-57	7201-7205	scan	_
42-58	7206-7209	for	_
42-59	7210-7213	VBM	_
42-60	7214-7222	analysis	_
42-61	7223-7224	.	_

Text=Preprocessing Structural data preprocessing and analysis for this study was performed with the VBM8 toolbox (http: //dbm.neuro.uni-jena.de/vbm/) within the Statistical Parametric Mapping software SPM8 (Wellcome Department of Imaging Neuroscience, Institute of Neurology and the National Hospital for Neurology and Neurosurgery; London, England; http: //www.fil.ion.ucl.ac.uk/spm/) running on MATLAB R2014a (Mathworks).
43-1	7225-7238	Preprocessing	_
43-2	7239-7249	Structural	_
43-3	7250-7254	data	_
43-4	7255-7268	preprocessing	_
43-5	7269-7272	and	_
43-6	7273-7281	analysis	_
43-7	7282-7285	for	_
43-8	7286-7290	this	_
43-9	7291-7296	study	_
43-10	7297-7300	was	_
43-11	7301-7310	performed	_
43-12	7311-7315	with	_
43-13	7316-7319	the	_
43-14	7320-7324	VBM8	_
43-15	7325-7332	toolbox	_
43-16	7333-7334	(	_
43-17	7335-7339	http	_
43-18	7340-7341	:	_
43-19	7342-7370	//dbm.neuro.uni-jena.de/vbm/	_
43-20	7371-7372	)	_
43-21	7373-7379	within	_
43-22	7380-7383	the	_
43-23	7384-7395	Statistical	_
43-24	7396-7406	Parametric	_
43-25	7407-7414	Mapping	_
43-26	7415-7423	software	_
43-27	7424-7428	SPM8	_
43-28	7429-7430	(	_
43-29	7431-7439	Wellcome	_
43-30	7440-7450	Department	_
43-31	7451-7453	of	_
43-32	7454-7461	Imaging	_
43-33	7462-7474	Neuroscience	_
43-34	7475-7476	,	_
43-35	7477-7486	Institute	_
43-36	7487-7489	of	_
43-37	7490-7499	Neurology	_
43-38	7500-7503	and	_
43-39	7504-7507	the	_
43-40	7508-7516	National	_
43-41	7517-7525	Hospital	_
43-42	7526-7529	for	_
43-43	7530-7539	Neurology	_
43-44	7540-7543	and	_
43-45	7544-7556	Neurosurgery	_
43-46	7557-7558	;	_
43-47	7559-7565	London	_
43-48	7566-7567	,	_
43-49	7568-7575	England	_
43-50	7576-7577	;	_
43-51	7578-7582	http	_
43-52	7583-7584	:	_
43-53	7585-7613	//www.fil.ion.ucl.ac.uk/spm/	_
43-54	7614-7615	)	_
43-55	7616-7623	running	_
43-56	7624-7626	on	_
43-57	7627-7633	MATLAB	_
43-58	7634-7640	R2014a	_
43-59	7641-7642	(	_
43-60	7643-7652	Mathworks	_
43-61	7653-7654	)	_
43-62	7655-7656	.	_

Text=The VBM8 toolbox was used for structural data preprocessing and to check the quality of the data.
44-1	7657-7660	The	_
44-2	7661-7665	VBM8	_
44-3	7666-7673	toolbox	_
44-4	7674-7677	was	_
44-5	7678-7682	used	_
44-6	7683-7686	for	_
44-7	7687-7697	structural	_
44-8	7698-7702	data	_
44-9	7703-7716	preprocessing	_
44-10	7717-7720	and	_
44-11	7721-7723	to	_
44-12	7724-7729	check	_
44-13	7730-7733	the	_
44-14	7734-7741	quality	_
44-15	7742-7744	of	_
44-16	7745-7748	the	_
44-17	7749-7753	data	_
44-18	7754-7755	.	_

Text=Preprocessing was done using the “ estimate and run ” module that performs bias correction, tissue segmentation, affine registration, normalization, and modulation.
45-1	7756-7769	Preprocessing	_
45-2	7770-7773	was	_
45-3	7774-7778	done	_
45-4	7779-7784	using	_
45-5	7785-7788	the	_
45-6	7789-7790	“	_
45-7	7791-7799	estimate	_
45-8	7800-7803	and	_
45-9	7804-7807	run	_
45-10	7808-7809	”	_
45-11	7810-7816	module	_
45-12	7817-7821	that	_
45-13	7822-7830	performs	_
45-14	7831-7835	bias	_
45-15	7836-7846	correction	_
45-16	7847-7848	,	_
45-17	7849-7855	tissue	_
45-18	7856-7868	segmentation	_
45-19	7869-7870	,	_
45-20	7871-7877	affine	_
45-21	7878-7890	registration	_
45-22	7891-7892	,	_
45-23	7893-7906	normalization	_
45-24	7907-7908	,	_
45-25	7909-7912	and	_
45-26	7913-7923	modulation	_
45-27	7924-7925	.	_

Text=VBM8 uses a maximum posteriori method for segment tissue types.
46-1	7926-7930	VBM8	_
46-2	7931-7935	uses	_
46-3	7936-7937	a	_
46-4	7938-7945	maximum	_
46-5	7946-7956	posteriori	_
46-6	7957-7963	method	_
46-7	7964-7967	for	_
46-8	7968-7975	segment	_
46-9	7976-7982	tissue	_
46-10	7983-7988	types	_
46-11	7989-7990	.	_

Text=Segmented images were normalized to Montreal Neurological Institute (MNI) space using nonlinear DARTEL normalization.
47-1	7991-8000	Segmented	_
47-2	8001-8007	images	_
47-3	8008-8012	were	_
47-4	8013-8023	normalized	_
47-5	8024-8026	to	_
47-6	8027-8035	Montreal	_
47-7	8036-8048	Neurological	_
47-8	8049-8058	Institute	_
47-9	8059-8060	(	_
47-10	8061-8064	MNI	_
47-11	8065-8066	)	_
47-12	8067-8072	space	_
47-13	8073-8078	using	_
47-14	8079-8088	nonlinear	_
47-15	8089-8095	DARTEL	_
47-16	8096-8109	normalization	_
47-17	8110-8111	.	_

Text=These quality controlled modulated images were then smoothed using a 12mm full-width at half-maximum (FWHM) isotropic Gaussian kernel.
48-1	8112-8117	These	_
48-2	8118-8125	quality	_
48-3	8126-8136	controlled	_
48-4	8137-8146	modulated	_
48-5	8147-8153	images	_
48-6	8154-8158	were	_
48-7	8159-8163	then	_
48-8	8164-8172	smoothed	_
48-9	8173-8178	using	_
48-10	8179-8180	a	_
48-11	8181-8185	12mm	_
48-12	8186-8196	full-width	_
48-13	8197-8199	at	_
48-14	8200-8212	half-maximum	_
48-15	8213-8214	(	_
48-16	8215-8219	FWHM	_
48-17	8220-8221	)	_
48-18	8222-8231	isotropic	_
48-19	8232-8240	Gaussian	_
48-20	8241-8247	kernel	_
48-21	8248-8249	.	_

Text=The resulting SPM contrasts maps were thresholded with p <0.005 with a cluster size of 200 voxels.
49-1	8250-8253	The	_
49-2	8254-8263	resulting	_
49-3	8264-8267	SPM	_
49-4	8268-8277	contrasts	_
49-5	8278-8282	maps	_
49-6	8283-8287	were	_
49-7	8288-8299	thresholded	_
49-8	8300-8304	with	_
49-9	8305-8306	p	_
49-10	8307-8308	<	_
49-11	8309-8314	0.005	_
49-12	8315-8319	with	_
49-13	8320-8321	a	_
49-14	8322-8329	cluster	_
49-15	8330-8334	size	_
49-16	8335-8337	of	_
49-17	8338-8341	200	_
49-18	8342-8348	voxels	_
49-19	8349-8350	.	_

Text=The significance of these thresholded clusters was determined using a family wise error (FWE) correction threshold which was set at p=0.05.
50-1	8351-8354	The	_
50-2	8355-8367	significance	_
50-3	8368-8370	of	_
50-4	8371-8376	these	_
50-5	8377-8388	thresholded	_
50-6	8389-8397	clusters	_
50-7	8398-8401	was	_
50-8	8402-8412	determined	_
50-9	8413-8418	using	_
50-10	8419-8420	a	_
50-11	8421-8427	family	_
50-12	8428-8432	wise	_
50-13	8433-8438	error	_
50-14	8439-8440	(	_
50-15	8441-8444	FWE	_
50-16	8445-8446	)	_
50-17	8447-8457	correction	_
50-18	8458-8467	threshold	_
50-19	8468-8473	which	_
50-20	8474-8477	was	_
50-21	8478-8481	set	_
50-22	8482-8484	at	_
50-23	8485-8491	p=0.05	_
50-24	8492-8493	.	_

Text=Additionally, regional volumes were calculated using the MarsBaR ROI toolbox (http: //marsbar.sourceforge.net) to compare the gray matter (GM) volume of the specified regions of interest (ROIs) which were further compared in SPSS (version 20).
51-1	8494-8506	Additionally	_
51-2	8507-8508	,	_
51-3	8509-8517	regional	_
51-4	8518-8525	volumes	_
51-5	8526-8530	were	_
51-6	8531-8541	calculated	_
51-7	8542-8547	using	_
51-8	8548-8551	the	_
51-9	8552-8559	MarsBaR	_
51-10	8560-8563	ROI	_
51-11	8564-8571	toolbox	_
51-12	8572-8573	(	_
51-13	8574-8578	http	_
51-14	8579-8580	:	_
51-15	8581-8606	//marsbar.sourceforge.net	_
51-16	8607-8608	)	_
51-17	8609-8611	to	_
51-18	8612-8619	compare	_
51-19	8620-8623	the	_
51-20	8624-8628	gray	_
51-21	8629-8635	matter	_
51-22	8636-8637	(	_
51-23	8638-8640	GM	_
51-24	8641-8642	)	_
51-25	8643-8649	volume	_
51-26	8650-8652	of	_
51-27	8653-8656	the	_
51-28	8657-8666	specified	_
51-29	8667-8674	regions	_
51-30	8675-8677	of	_
51-31	8678-8686	interest	_
51-32	8687-8688	(	_
51-33	8689-8693	ROIs	_
51-34	8694-8695	)	_
51-35	8696-8701	which	_
51-36	8702-8706	were	_
51-37	8707-8714	further	_
51-38	8715-8723	compared	_
51-39	8724-8726	in	_
51-40	8727-8731	SPSS	_
51-41	8732-8733	(	_
51-42	8734-8741	version	_
51-43	8742-8744	20	_
51-44	8745-8746	)	_
51-45	8747-8748	.	_

Text=ROIs were calculated for each participant and entered into SPSS analyses along with multiple covariates to follow up on areas revealed in the whole brain analyses.
52-1	8749-8753	ROIs	_
52-2	8754-8758	were	_
52-3	8759-8769	calculated	_
52-4	8770-8773	for	_
52-5	8774-8778	each	_
52-6	8779-8790	participant	_
52-7	8791-8794	and	_
52-8	8795-8802	entered	_
52-9	8803-8807	into	_
52-10	8808-8812	SPSS	_
52-11	8813-8821	analyses	_
52-12	8822-8827	along	_
52-13	8828-8832	with	_
52-14	8833-8841	multiple	_
52-15	8842-8852	covariates	_
52-16	8853-8855	to	_
52-17	8856-8862	follow	_
52-18	8863-8865	up	_
52-19	8866-8868	on	_
52-20	8869-8874	areas	_
52-21	8875-8883	revealed	_
52-22	8884-8886	in	_
52-23	8887-8890	the	_
52-24	8891-8896	whole	_
52-25	8897-8902	brain	_
52-26	8903-8911	analyses	_
52-27	8912-8913	.	_

Text=VBM Whole Brain Statistical Analysis Structural MRI data from 19 subjects did not pass our data quality standards and were excluded from further analysis.
53-1	8914-8917	VBM	_
53-2	8918-8923	Whole	_
53-3	8924-8929	Brain	_
53-4	8930-8941	Statistical	_
53-5	8942-8950	Analysis	_
53-6	8951-8961	Structural	_
53-7	8962-8965	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
53-8	8966-8970	data	_
53-9	8971-8975	from	_
53-10	8976-8978	19	_
53-11	8979-8987	subjects	_
53-12	8988-8991	did	_
53-13	8992-8995	not	_
53-14	8996-9000	pass	_
53-15	9001-9004	our	_
53-16	9005-9009	data	_
53-17	9010-9017	quality	_
53-18	9018-9027	standards	_
53-19	9028-9031	and	_
53-20	9032-9036	were	_
53-21	9037-9045	excluded	_
53-22	9046-9050	from	_
53-23	9051-9058	further	_
53-24	9059-9067	analysis	_
53-25	9068-9069	.	_

Text=Reasons for exclusion included not passing the manual quality inspection due to structural abnormalities (N=4), poor quality of skull stripping (N=5), and poor gray matter image quality associated with extreme covariance parameters (N=10).
54-1	9070-9077	Reasons	_
54-2	9078-9081	for	_
54-3	9082-9091	exclusion	_
54-4	9092-9100	included	_
54-5	9101-9104	not	_
54-6	9105-9112	passing	_
54-7	9113-9116	the	_
54-8	9117-9123	manual	_
54-9	9124-9131	quality	_
54-10	9132-9142	inspection	_
54-11	9143-9146	due	_
54-12	9147-9149	to	_
54-13	9150-9160	structural	_
54-14	9161-9174	abnormalities	_
54-15	9175-9176	(	_
54-16	9177-9180	N=4	_
54-17	9181-9182	)	_
54-18	9183-9184	,	_
54-19	9185-9189	poor	_
54-20	9190-9197	quality	_
54-21	9198-9200	of	_
54-22	9201-9206	skull	_
54-23	9207-9216	stripping	_
54-24	9217-9218	(	_
54-25	9219-9222	N=5	_
54-26	9223-9224	)	_
54-27	9225-9226	,	_
54-28	9227-9230	and	_
54-29	9231-9235	poor	_
54-30	9236-9240	gray	_
54-31	9241-9247	matter	_
54-32	9248-9253	image	_
54-33	9254-9261	quality	_
54-34	9262-9272	associated	_
54-35	9273-9277	with	_
54-36	9278-9285	extreme	_
54-37	9286-9296	covariance	_
54-38	9297-9307	parameters	_
54-39	9308-9309	(	_
54-40	9310-9314	N=10	_
54-41	9315-9316	)	_
54-42	9317-9318	.	_

Text=The remaining 88 scans, 43 HR offspring (Mean age 27.4 ± 3.6 years) and 45 LR offspring (Mean age 24.5 ± 4.1 years) were available for the VBM analysis.
55-1	9319-9322	The	_
55-2	9323-9332	remaining	_
55-3	9333-9335	88	_
55-4	9336-9341	scans	_
55-5	9342-9343	,	_
55-6	9344-9346	43	_
55-7	9347-9349	HR	_
55-8	9350-9359	offspring	_
55-9	9360-9361	(	_
55-10	9362-9366	Mean	_
55-11	9367-9370	age	_
55-12	9371-9375	27.4	_
55-13	9376-9377	±	_
55-14	9378-9381	3.6	_
55-15	9382-9387	years	_
55-16	9388-9389	)	_
55-17	9390-9393	and	_
55-18	9394-9396	45	_
55-19	9397-9399	LR	_
55-20	9400-9409	offspring	_
55-21	9410-9411	(	_
55-22	9412-9416	Mean	_
55-23	9417-9420	age	_
55-24	9421-9425	24.5	_
55-25	9426-9427	±	_
55-26	9428-9431	4.1	_
55-27	9432-9437	years	_
55-28	9438-9439	)	_
55-29	9440-9444	were	_
55-30	9445-9454	available	_
55-31	9455-9458	for	_
55-32	9459-9462	the	_
55-33	9463-9466	VBM	_
55-34	9467-9475	analysis	_
55-35	9476-9477	.	_

Text=Cumulative estimates of personal exposure to alcohol, drugs, and cigarettes along with diagnoses concerning alcohol abuse, alcohol dependence, drug abuse and drug dependence up to the time of the MRI scan were available for all 88 subjects who had participated in the longitudinal follow-up.
56-1	9478-9488	Cumulative	_
56-2	9489-9498	estimates	_
56-3	9499-9501	of	_
56-4	9502-9510	personal	_
56-5	9511-9519	exposure	_
56-6	9520-9522	to	_
56-7	9523-9530	alcohol	_
56-8	9531-9532	,	_
56-9	9533-9538	drugs	_
56-10	9539-9540	,	_
56-11	9541-9544	and	_
56-12	9545-9555	cigarettes	_
56-13	9556-9561	along	_
56-14	9562-9566	with	_
56-15	9567-9576	diagnoses	_
56-16	9577-9587	concerning	_
56-17	9588-9595	alcohol	_
56-18	9596-9601	abuse	_
56-19	9602-9603	,	_
56-20	9604-9611	alcohol	_
56-21	9612-9622	dependence	_
56-22	9623-9624	,	_
56-23	9625-9629	drug	_
56-24	9630-9635	abuse	_
56-25	9636-9639	and	_
56-26	9640-9644	drug	_
56-27	9645-9655	dependence	_
56-28	9656-9658	up	_
56-29	9659-9661	to	_
56-30	9662-9665	the	_
56-31	9666-9670	time	_
56-32	9671-9673	of	_
56-33	9674-9677	the	_
56-34	9678-9681	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
56-35	9682-9686	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
56-36	9687-9691	were	_
56-37	9692-9701	available	_
56-38	9702-9705	for	_
56-39	9706-9709	all	_
56-40	9710-9712	88	_
56-41	9713-9721	subjects	_
56-42	9722-9725	who	_
56-43	9726-9729	had	_
56-44	9730-9742	participated	_
56-45	9743-9745	in	_
56-46	9746-9749	the	_
56-47	9750-9762	longitudinal	_
56-48	9763-9772	follow-up	_
56-49	9773-9774	.	_

Text=Substance use disorder was defined as presence of either alcohol abuse or dependence, or drug abuse or dependence.
57-1	9775-9784	Substance	_
57-2	9785-9788	use	_
57-3	9789-9797	disorder	_
57-4	9798-9801	was	_
57-5	9802-9809	defined	_
57-6	9810-9812	as	_
57-7	9813-9821	presence	_
57-8	9822-9824	of	_
57-9	9825-9831	either	_
57-10	9832-9839	alcohol	_
57-11	9840-9845	abuse	_
57-12	9846-9848	or	_
57-13	9849-9859	dependence	_
57-14	9860-9861	,	_
57-15	9862-9864	or	_
57-16	9865-9869	drug	_
57-17	9870-9875	abuse	_
57-18	9876-9878	or	_
57-19	9879-9889	dependence	_
57-20	9890-9891	.	_

Text=The mothers ’ use of alcohol, drugs, and cigarettes was not available for some participants (alcohol and drug exposure [N=8], cigarette use [N=5]).
58-1	9892-9895	The	_
58-2	9896-9903	mothers	_
58-3	9904-9905	’	_
58-4	9906-9909	use	_
58-5	9910-9912	of	_
58-6	9913-9920	alcohol	_
58-7	9921-9922	,	_
58-8	9923-9928	drugs	_
58-9	9929-9930	,	_
58-10	9931-9934	and	_
58-11	9935-9945	cigarettes	_
58-12	9946-9949	was	_
58-13	9950-9953	not	_
58-14	9954-9963	available	_
58-15	9964-9967	for	_
58-16	9968-9972	some	_
58-17	9973-9985	participants	_
58-18	9986-9987	(	_
58-19	9988-9995	alcohol	_
58-20	9996-9999	and	_
58-21	10000-10004	drug	_
58-22	10005-10013	exposure	_
58-23	10014-10015	[	_
58-24	10016-10019	N=8	_
58-25	10020-10021	]	_
58-26	10022-10023	,	_
58-27	10024-10033	cigarette	_
58-28	10034-10037	use	_
58-29	10038-10039	[	_
58-30	10040-10043	N=5	_
58-31	10044-10045	]	_
58-32	10046-10047	)	_
58-33	10048-10049	.	_

Text=A total of 75 subjects (HR=36, LR=39) had complete prenatal use data for VBM analysis.
59-1	10050-10051	A	_
59-2	10052-10057	total	_
59-3	10058-10060	of	_
59-4	10061-10063	75	_
59-5	10064-10072	subjects	_
59-6	10073-10074	(	_
59-7	10075-10080	HR=36	_
59-8	10081-10082	,	_
59-9	10083-10088	LR=39	_
59-10	10089-10090	)	_
59-11	10091-10094	had	_
59-12	10095-10103	complete	_
59-13	10104-10112	prenatal	_
59-14	10113-10116	use	_
59-15	10117-10121	data	_
59-16	10122-10125	for	_
59-17	10126-10129	VBM	_
59-18	10130-10138	analysis	_
59-19	10139-10140	.	_

Text=Personal use of substances up to the time of the scan was considered by coding each subject for presence or absence of a substance use disorder (SUD).
60-1	10141-10149	Personal	_
60-2	10150-10153	use	_
60-3	10154-10156	of	_
60-4	10157-10167	substances	_
60-5	10168-10170	up	_
60-6	10171-10173	to	_
60-7	10174-10177	the	_
60-8	10178-10182	time	_
60-9	10183-10185	of	_
60-10	10186-10189	the	_
60-11	10190-10194	scan	_
60-12	10195-10198	was	_
60-13	10199-10209	considered	_
60-14	10210-10212	by	_
60-15	10213-10219	coding	_
60-16	10220-10224	each	_
60-17	10225-10232	subject	_
60-18	10233-10236	for	_
60-19	10237-10245	presence	_
60-20	10246-10248	or	_
60-21	10249-10256	absence	_
60-22	10257-10259	of	_
60-23	10260-10261	a	_
60-24	10262-10271	substance	_
60-25	10272-10275	use	_
60-26	10276-10284	disorder	_
60-27	10285-10286	(	_
60-28	10287-10290	SUD	_
60-29	10291-10292	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
60-30	10293-10294	.	_

Text=For the purpose of stratifying the level of prenatal exposure for the SPM analyses, the median number of drinks for those who reported any drinking during pregnancy was first determined.
61-1	10295-10298	For	_
61-2	10299-10302	the	_
61-3	10303-10310	purpose	_
61-4	10311-10313	of	_
61-5	10314-10325	stratifying	_
61-6	10326-10329	the	_
61-7	10330-10335	level	_
61-8	10336-10338	of	_
61-9	10339-10347	prenatal	_
61-10	10348-10356	exposure	_
61-11	10357-10360	for	_
61-12	10361-10364	the	_
61-13	10365-10368	SPM	_
61-14	10369-10377	analyses	_
61-15	10378-10379	,	_
61-16	10380-10383	the	_
61-17	10384-10390	median	_
61-18	10391-10397	number	_
61-19	10398-10400	of	_
61-20	10401-10407	drinks	_
61-21	10408-10411	for	_
61-22	10412-10417	those	_
61-23	10418-10421	who	_
61-24	10422-10430	reported	_
61-25	10431-10434	any	_
61-26	10435-10443	drinking	_
61-27	10444-10450	during	_
61-28	10451-10460	pregnancy	_
61-29	10461-10464	was	_
61-30	10465-10470	first	_
61-31	10471-10481	determined	_
61-32	10482-10483	.	_

Text=Those mothers who reported no drinking or drinking less than the median for the sample were classified as no or low exposure mothers and those with drinking above the median as high exposure.
62-1	10484-10489	Those	_
62-2	10490-10497	mothers	_
62-3	10498-10501	who	_
62-4	10502-10510	reported	_
62-5	10511-10513	no	_
62-6	10514-10522	drinking	_
62-7	10523-10525	or	_
62-8	10526-10534	drinking	_
62-9	10535-10539	less	_
62-10	10540-10544	than	_
62-11	10545-10548	the	_
62-12	10549-10555	median	_
62-13	10556-10559	for	_
62-14	10560-10563	the	_
62-15	10564-10570	sample	_
62-16	10571-10575	were	_
62-17	10576-10586	classified	_
62-18	10587-10589	as	_
62-19	10590-10592	no	_
62-20	10593-10595	or	_
62-21	10596-10599	low	_
62-22	10600-10608	exposure	_
62-23	10609-10616	mothers	_
62-24	10617-10620	and	_
62-25	10621-10626	those	_
62-26	10627-10631	with	_
62-27	10632-10640	drinking	_
62-28	10641-10646	above	_
62-29	10647-10650	the	_
62-30	10651-10657	median	_
62-31	10658-10660	as	_
62-32	10661-10665	high	_
62-33	10666-10674	exposure	_
62-34	10675-10676	.	_

Text=Accordingly, offspring who had prenatal exposure equal to or greater than 54 drinks during the pregnancy were categorized as prenatally exposed and those with mothers reporting less than 53 drinks were considered to be prenatally low or unexposed.
63-1	10677-10688	Accordingly	_
63-2	10689-10690	,	_
63-3	10691-10700	offspring	_
63-4	10701-10704	who	_
63-5	10705-10708	had	_
63-6	10709-10717	prenatal	_
63-7	10718-10726	exposure	_
63-8	10727-10732	equal	_
63-9	10733-10735	to	_
63-10	10736-10738	or	_
63-11	10739-10746	greater	_
63-12	10747-10751	than	_
63-13	10752-10754	54	_
63-14	10755-10761	drinks	_
63-15	10762-10768	during	_
63-16	10769-10772	the	_
63-17	10773-10782	pregnancy	_
63-18	10783-10787	were	_
63-19	10788-10799	categorized	_
63-20	10800-10802	as	_
63-21	10803-10813	prenatally	_
63-22	10814-10821	exposed	_
63-23	10822-10825	and	_
63-24	10826-10831	those	_
63-25	10832-10836	with	_
63-26	10837-10844	mothers	_
63-27	10845-10854	reporting	_
63-28	10855-10859	less	_
63-29	10860-10864	than	_
63-30	10865-10867	53	_
63-31	10868-10874	drinks	_
63-32	10875-10879	were	_
63-33	10880-10890	considered	_
63-34	10891-10893	to	_
63-35	10894-10896	be	_
63-36	10897-10907	prenatally	_
63-37	10908-10911	low	_
63-38	10912-10914	or	_
63-39	10915-10924	unexposed	_
63-40	10925-10926	.	_

Text=To provide a more refined estimate of prenatal effects on offspring, comparisons were made between those grouped by whether the mother did not drink during pregnancy (nonexposed) versus those who drank less than the median (low-exposure), and again using the nonexposed versus those with mothers having greater than the median use (high-exposure).
64-1	10927-10929	To	_
64-2	10930-10937	provide	_
64-3	10938-10939	a	_
64-4	10940-10944	more	_
64-5	10945-10952	refined	_
64-6	10953-10961	estimate	_
64-7	10962-10964	of	_
64-8	10965-10973	prenatal	_
64-9	10974-10981	effects	_
64-10	10982-10984	on	_
64-11	10985-10994	offspring	_
64-12	10995-10996	,	_
64-13	10997-11008	comparisons	_
64-14	11009-11013	were	_
64-15	11014-11018	made	_
64-16	11019-11026	between	_
64-17	11027-11032	those	_
64-18	11033-11040	grouped	_
64-19	11041-11043	by	_
64-20	11044-11051	whether	_
64-21	11052-11055	the	_
64-22	11056-11062	mother	_
64-23	11063-11066	did	_
64-24	11067-11070	not	_
64-25	11071-11076	drink	_
64-26	11077-11083	during	_
64-27	11084-11093	pregnancy	_
64-28	11094-11095	(	_
64-29	11096-11106	nonexposed	_
64-30	11107-11108	)	_
64-31	11109-11115	versus	_
64-32	11116-11121	those	_
64-33	11122-11125	who	_
64-34	11126-11131	drank	_
64-35	11132-11136	less	_
64-36	11137-11141	than	_
64-37	11142-11145	the	_
64-38	11146-11152	median	_
64-39	11153-11154	(	_
64-40	11155-11167	low-exposure	_
64-41	11168-11169	)	_
64-42	11170-11171	,	_
64-43	11172-11175	and	_
64-44	11176-11181	again	_
64-45	11182-11187	using	_
64-46	11188-11191	the	_
64-47	11192-11202	nonexposed	_
64-48	11203-11209	versus	_
64-49	11210-11215	those	_
64-50	11216-11220	with	_
64-51	11221-11228	mothers	_
64-52	11229-11235	having	_
64-53	11236-11243	greater	_
64-54	11244-11248	than	_
64-55	11249-11252	the	_
64-56	11253-11259	median	_
64-57	11260-11263	use	_
64-58	11264-11265	(	_
64-59	11266-11279	high-exposure	_
64-60	11280-11281	)	_
64-61	11282-11283	.	_

Text=SPSS Region of Interest Statistical Analysis An SPSS mixed model analysis was performed on the clusters of brain structures showing significant (FWE corrected) differences in our whole brain VBM analysis.
65-1	11284-11288	SPSS	_
65-2	11289-11295	Region	_
65-3	11296-11298	of	_
65-4	11299-11307	Interest	_
65-5	11308-11319	Statistical	_
65-6	11320-11328	Analysis	_
65-7	11329-11331	An	_
65-8	11332-11336	SPSS	_
65-9	11337-11342	mixed	_
65-10	11343-11348	model	_
65-11	11349-11357	analysis	_
65-12	11358-11361	was	_
65-13	11362-11371	performed	_
65-14	11372-11374	on	_
65-15	11375-11378	the	_
65-16	11379-11387	clusters	_
65-17	11388-11390	of	_
65-18	11391-11396	brain	_
65-19	11397-11407	structures	_
65-20	11408-11415	showing	_
65-21	11416-11427	significant	_
65-22	11428-11429	(	_
65-23	11430-11433	FWE	_
65-24	11434-11443	corrected	_
65-25	11444-11445	)	_
65-26	11446-11457	differences	_
65-27	11458-11460	in	_
65-28	11461-11464	our	_
65-29	11465-11470	whole	_
65-30	11471-11476	brain	_
65-31	11477-11480	VBM	_
65-32	11481-11489	analysis	_
65-33	11490-11491	.	_

Text=The volumes of these brain structures were extracted using MarsBaR and used in SPSS based mixed model analysis to provide statistical control for participants from families with multiple siblings using a family ID variable.
66-1	11492-11495	The	_
66-2	11496-11503	volumes	_
66-3	11504-11506	of	_
66-4	11507-11512	these	_
66-5	11513-11518	brain	_
66-6	11519-11529	structures	_
66-7	11530-11534	were	_
66-8	11535-11544	extracted	_
66-9	11545-11550	using	_
66-10	11551-11558	MarsBaR	_
66-11	11559-11562	and	_
66-12	11563-11567	used	_
66-13	11568-11570	in	_
66-14	11571-11575	SPSS	_
66-15	11576-11581	based	_
66-16	11582-11587	mixed	_
66-17	11588-11593	model	_
66-18	11594-11602	analysis	_
66-19	11603-11605	to	_
66-20	11606-11613	provide	_
66-21	11614-11625	statistical	_
66-22	11626-11633	control	_
66-23	11634-11637	for	_
66-24	11638-11650	participants	_
66-25	11651-11655	from	_
66-26	11656-11664	families	_
66-27	11665-11669	with	_
66-28	11670-11678	multiple	_
66-29	11679-11687	siblings	_
66-30	11688-11693	using	_
66-31	11694-11695	a	_
66-32	11696-11702	family	_
66-33	11703-11705	ID	_
66-34	11706-11714	variable	_
66-35	11715-11716	.	_

Text=Using the same covariates used in the VBM analysis, we investigated the effect of familial risk and the effect of prenatal alcohol exposure on gray matter volume.
67-1	11717-11722	Using	_
67-2	11723-11726	the	_
67-3	11727-11731	same	_
67-4	11732-11742	covariates	_
67-5	11743-11747	used	_
67-6	11748-11750	in	_
67-7	11751-11754	the	_
67-8	11755-11758	VBM	_
67-9	11759-11767	analysis	_
67-10	11768-11769	,	_
67-11	11770-11772	we	_
67-12	11773-11785	investigated	_
67-13	11786-11789	the	_
67-14	11790-11796	effect	_
67-15	11797-11799	of	_
67-16	11800-11808	familial	_
67-17	11809-11813	risk	_
67-18	11814-11817	and	_
67-19	11818-11821	the	_
67-20	11822-11828	effect	_
67-21	11829-11831	of	_
67-22	11832-11840	prenatal	_
67-23	11841-11848	alcohol	_
67-24	11849-11857	exposure	_
67-25	11858-11860	on	_
67-26	11861-11865	gray	_
67-27	11866-11872	matter	_
67-28	11873-11879	volume	_
67-29	11880-11881	.	_

Text=HR subjects were compared to LR subjects, and within the HR group, those with prenatal alcohol exposure were compared with HR subjects who had no or low prenatal alcohol exposure.
68-1	11882-11884	HR	http://maven.renci.org/NeuroBridge/neurobridge#AcuteDepression
68-2	11885-11893	subjects	_
68-3	11894-11898	were	_
68-4	11899-11907	compared	_
68-5	11908-11910	to	_
68-6	11911-11913	LR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
68-7	11914-11922	subjects	_
68-8	11923-11924	,	_
68-9	11925-11928	and	_
68-10	11929-11935	within	_
68-11	11936-11939	the	_
68-12	11940-11942	HR	_
68-13	11943-11948	group	_
68-14	11949-11950	,	_
68-15	11951-11956	those	_
68-16	11957-11961	with	_
68-17	11962-11970	prenatal	_
68-18	11971-11978	alcohol	_
68-19	11979-11987	exposure	_
68-20	11988-11992	were	_
68-21	11993-12001	compared	_
68-22	12002-12006	with	_
68-23	12007-12009	HR	http://maven.renci.org/NeuroBridge/neurobridge#AcuteDepression
68-24	12010-12018	subjects	_
68-25	12019-12022	who	_
68-26	12023-12026	had	_
68-27	12027-12029	no	_
68-28	12030-12032	or	_
68-29	12033-12036	low	_
68-30	12037-12045	prenatal	_
68-31	12046-12053	alcohol	_
68-32	12054-12062	exposure	_
68-33	12063-12064	.	_

Text=The cumulative estimates of personal use of alcohol, drugs and cigarettes available from longitudinal data collection were used as quantitative variables in the SPSS analyses.
69-1	12065-12068	The	_
69-2	12069-12079	cumulative	_
69-3	12080-12089	estimates	_
69-4	12090-12092	of	_
69-5	12093-12101	personal	_
69-6	12102-12105	use	_
69-7	12106-12108	of	_
69-8	12109-12116	alcohol	_
69-9	12117-12118	,	_
69-10	12119-12124	drugs	_
69-11	12125-12128	and	_
69-12	12129-12139	cigarettes	_
69-13	12140-12149	available	_
69-14	12150-12154	from	_
69-15	12155-12167	longitudinal	_
69-16	12168-12172	data	_
69-17	12173-12183	collection	_
69-18	12184-12188	were	_
69-19	12189-12193	used	_
69-20	12194-12196	as	_
69-21	12197-12209	quantitative	_
69-22	12210-12219	variables	_
69-23	12220-12222	in	_
69-24	12223-12226	the	_
69-25	12227-12231	SPSS	_
69-26	12232-12240	analyses	_
69-27	12241-12242	.	_

